Osaka, Japan and Durham, N.C., July 10, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) and its partner, Zinfandel Pharmaceuticals, Inc. (“Zinfandel”), will present data during multiple poster and oral sessions at the upcoming Alzheimer’s Association International Conference® 2014 (AAIC®), taking place in Copenhagen, Denmark from July 12-17, 2014.
“Studies show that individuals with mild cognitive impairment—a slight, although noticeable and measurable decline in cognitive abilities—are at an increased risk of developing Alzheimer’s disease or another dementia. An option to be able to predict an individual’s risk for developing this disease would be welcomed by the medical community,” said Stephen Brannan, M.D., Central Nervous System Development Therapeutic Area Head, Takeda. “Therefore, a special focus for Takeda at this conference will be presenting updates on the TOMMORROW Trial—a trial that challenges the status quo and aims to accelerate the progress toward identifying effective therapeutic agents for Alzheimer’s disease.”
Takeda presentations at AAIC® 2014 are as follows:
Monday, July 14, 2014
Poster No: P2-392
Poster Title: Cross-Cultural Validation and Normative Study of a Neuropsychological Battery Used in the Determination of Clinical Endpoints to Delay Onset of MCI
Authors: Kathleen A. Welsh-Bohmer, Heather R. Romero, Kathleen M. Hayden, Brenda L. Plassman, Alexandra Atkins, Adam Vaughan, Nicole Turcotte, Richard S. E. Keefe, Oksana Makeeva, Andreas U. Monsch, Giovanni B. Frisoni, Zara Melikyan, Shyama Brewster, Carl Chiang, Janet O’Neil, Jennifer Schuster, Margarita Lymboura, Grant Runyan, Mark Atkinson, Kumar Budur for the TOMMORROW Study Investigators
Location: Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)
Tuesday, July 15, 2014
Poster No: P3-398
Poster Title: Deriving an Informed Neurocognitive Composite Measure for Delay of Onset Trials in Mild Cognitive Impairment due to Alzheimer’s disease (MCI-AD)
Authors: Mark Espeland, Leslie Vaughan, Heather Romero, Kathleen M. Hayden, Brenda L. Plassman, Kathleen A. Welsh-Bohmer for the TOMMORROW Study Investigators
Location: Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)
Poster No: P3-021
Poster Title: Identification and Characterization of Polymorphic Structural Variants Associated with Alzheimer’s Disease and Diseases of Aging
Authors: Michael W. Lutz, Robert Saul, Daniel K. Burns, Ann M. Saunders, Allen D. Roses
Location: Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)
Poster No: P3-255
Poster Title: Cultural Adaptation of Translated Neurocognitive Assessments in Russia, Switzerland and Italy: Pilot Testing for a Program to Delay the Onset of Mild Cognitive Impairment due to Alzheimer’s Disease
Authors: Alexandra S. Atkins, Richard S. E. Keefe, Adam W. Vaughan, Nicole M. Turcotte, Oksana A. Makeeva, Andreas U. Monsch, Giovanni B. Frisoni, Maura Parapini, Zara A. Melikyan, Shyama Brewster, Janet O’Neil, Jennifer Schuster, Margarita Lymboura, Heather Romero, Kathleen M. Hayden, Brenda Plassman, Kathleen A. Welsh-Bohmer
Location: Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)
Wednesday, July 16, 2014
Session No: FTS-03
Session Title: The Collaboration for Alzheimer’s Prevention (CAP): Advancing the Evaluation of Alzheimer’s Prevention Therapies
Authors: Kathleen A. Welsh-Bohmer, Daniel K. Burns, Stephen K. Brannan, Kumar Budur for the TOMMORROW investigators
Location: Auditorium 15 (8:30 am - 10:00 am UTC)
Poster No: P4-073
Poster Title: A Pharmacogenetics Supported Clinical Trial to Delay Onset of Mild Cognitive Impairment Due to Alzheimer’s Disease Using Low Dose Pioglitazone: An Update on the TOMMORROW Study
Authors: Kumar Budur, Kathleen A. Welsh-Bohmer, Daniel K. Burns, Carl Chiang, Janet O’Neil, Grant Runyan, Marcia Cyganowski, Donna G. Crenshaw, Michael W. Lutz, Craig A. Metz, Ann M. Saunders, Deborah Yarbrough, David Yarnall, MS, Eric Lai, Stephen K. Brannan, Allen D. Roses
Location: Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)
Poster No: P4-284
Poster Title: Genetic Relationship of APOE and TOMM40 Haplotypes in African American, West African, and Caucasian Cohorts
Authors: Allen D. Roses, Michael W. Lutz, Robert Saul, Daniel K. Burns, Ann M. Saunders, Dmitry Goldgaber, Scott S. Sundseth, Patrick A. Akkari, Stephanie M. Roses, William K. Gottschalk, Keith E. Whitfield, Alexander A. Vostrov, Michael A. Hauser, R. Rand Allingham, Ornit Chiba-Falek, Kathleen A. Welsh-Bohmer
Location: Bella Center A/S, Center Boulevard 5, DK-2300 Copenhagen S (11:45 am - 2:15 pm UTC)
Session No: O4-07-01
Session Title: Effects of Pioglitazone on Mnemonic Hippocampal Function: A Pharmacologic BOLD fMRI Study in Healthy Elderly Subjects
Authors: Stephen K. Brannan, Ahmad R. Hariri, Annchen Knodt, Adam X. Gorka, James Burke, Kathleen Welsh-Bohmer, Brenda L. Plassman, Michael Kukulka, Daniel K. Burns, Allen D. Roses
Location: Hall C5A (4:00 pm - 5:30 pm UTC)
About the TOMMORROW Trial
The TOMMORROW trial is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The trial will use a genetic–based biomarker risk assignment algorithm comprised of apolipoprotein E (APOE) and Translocase of Outer Mitochondrial Membrane (TOMM40) genotypes and age, which is being studied to determine the risk of individuals developing mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) within a five year period. Cognitively normal individuals assessed as low risk will be assigned to receive placebo. Cognitively normal individuals assessed as high-risk will be assigned to low dose pioglitazone (AD-4833 0.8 SR mg QD) or placebo. The study duration is approximately five years or the time needed to achieve 410 conversions to MCI due to AD in the high-risk group. Approximately 5,800 cognitively normal individuals aged 65-83 at 60 centers worldwide will be randomized into the study. The study will recruit internationally from large, diverse, community-based populations.
The study has two objectives:
For the genetic-based biomarker risk assignment algorithm, the primary objective is to qualify the genetic-based biomarker risk algorithm to determine the risk of developing MCI due to AD within a five year period. The primary endpoint for the genetic-based biomarker risk algorithm is time to diagnosis of MCI due to AD for placebo-treated, high-risk subjects versus placebo-treated, low-risk subjects; and to evaluate the efficacy of the investigational agent, low dose pioglitazone (AD-4833 0.8 SR mg QD) in delaying the onset of MCI due to AD in cognitively normal individuals (aged 65-83) as determined by the genetic-based biomarker risk algorithm. The primary endpoint is time to diagnosis of MCI due to AD for pioglitazone (AD-4833 0.8 SR mg QD) treated subjects versus placebo-treated subjects in the high-risk stratum.
Key secondary objectives are to evaluate the effect of low dose pioglitazone (AD-4833 0.8 SR mg QD) versus placebo on the progression of cognitive decline and to compare the effects of low dose pioglitazone (AD-4833 0.8 SR mg QD) versus placebo on functional decline and instrumental activities of daily living.
For more information on the TOMMORROW trial, please visit: www.clinicaltrials.gov.
About Alzheimer’s Disease (AD) AD is a degenerative brain disease characterized by a progressive decline in memory, thinking, comprehension, calculation, language, learning capacity and judgment sufficient to impair personal activities of daily living. Approximately 18 million Americans are currently suffering from AD, and the rate of occurrence doubles every five years for those between 65 and 85 years of age. In the 2010 World Alzheimer Report, Alzheimer’s disease International estimated that there are 35.6 million people living with dementia worldwide in 2010, increasing to 65.7 million by 2030 and 115.4 million by 2050.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
About Zinfandel Pharmaceuticals
Zinfandel Pharmaceuticals, based in Durham, N.C., is a privately held company dedicated to using pharmacogenetics to improve prediction of risk for Alzheimer’s disease and thus facilitate the development of effective therapies.
Help employers find you! Check out all the jobs and post your resume.
